Moderna Inc [NASDAQ: MRNA] surged by $10949972.84 during the normal trading session on Monday and reaching a high of $28.74 during the day while it closed the day at $10950000.0.
Moderna Inc stock has also gained 7.48% of its value over the past 7 days. However, MRNA stock has declined by -11.34% in the 3 months of the year. Over the past six months meanwhile, it has lost -31.49% and lost -77.47% year-on date.
The market cap for MRNA stock reached $10.67 billion, with 387.00 million shares outstanding and 342.49 million shares in the current float. Compared to the average trading volume of 10.95M shares, MRNA reached a trading volume of 10148614 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $43.85 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 13, 2025. While these analysts kept the previous recommendation, Barclays raised their target price from $111 to $45. The new note on the price target was released on February 18, 2025, representing the official price target for Moderna Inc stock. Previously, the target price had yet another drop from $99 to $51, while Goldman kept a Neutral rating on MRNA stock.
The Price to Book ratio for the last quarter was 1.06, with the Price to Cash per share for the same quarter was set at 15.45.
MRNA stock trade performance evaluation
Moderna Inc [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.48. With this latest performance, MRNA shares gained by 2.45% in over the last four-week period, additionally sinking by -31.49% over the last 6 months – not to mention a drop of -33.65% in the past year of trading.
Moderna Inc [MRNA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc [MRNA] shares currently have an operating margin of -117.37% and a Gross Margin at 48.06%. Moderna Inc’s Net Margin is presently recorded at -105.67%.
Return on Equity for this stock declined to -22.81%, with Return on Assets sitting at -22.81%.
Earnings per share (EPS) analysis for Moderna Inc [MRNA] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc go to 20.72%.
Moderna Inc [MRNA]: Institutional Ownership
There are presently around $73.73%, or 79.52% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 43.45 million shares, which is approximately 11.3149%. VANGUARD GROUP INC, holding 39.56 million shares of the stock with an approximate value of $$4.7 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $$3.04 billion in MRNA stock with ownership which is approximately 6.6569%.
